Nexentis Technologies Inc.
NXTS
Last
$0.84
Day
-4.7%
1y
-87.7%
5y
-87.7%
52w
-96.3%
SPY YTD
+13.3%
XLB
+6.8%
Earnings
2026-11-1232d
EMA 21
1.36
EMA 50
1.80
EMA 200
3.90
20d high
-46.8%
5y high
-96.3%
5y range
0th
Positions held
Your positionsNXTS isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$1.18
Stop
$0.63
Stop distance
25.2%
Target vs last
+40.0%
Fundamentals
| Market cap | $1.28M | Enterprise value | -$7.29M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 0.67 | Beta | 1.86 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -4.5% | ROA | -29.5% | Debt / equity | 0.24 |
| Current ratio | 3.72 | Free cash flow | -$5.48M | Analyst recommendation | none | Mean target | — |
| 52w high | $32.90 | 52w low | $0.88 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | -$0.1M | $0.0M | $0.0M | — |
| Op margin | — | — | 863.2% | -66300.0% | — | — |
| Net income | -$11.1M | -$6.6M | $1.3M | $0.4M | -$4.5M | — |
| Gross margin | — | — | — | 0.0% | — | — |
| Gross profit | — | — | — | $0.0M | -$0.0M | $0.1M |
| Operating income | -$1.7M | -$2.3M | -$0.6M | -$1.3M | -$2.6M | — |
- Operating margin expanded to 863.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.3M | $0.4M | — |
| Op margin | — | — | -2865.8% | -1477.1% | — |
| Net income | -$4.0M | -$5.2M | -$6.5M | -$5.7M | — |
| Gross margin | — | — | 79.1% | 59.8% | — |
| Gross profit | — | $0.0M | $0.2M | $0.2M | $0.3M |
| Operating income | -$5.4M | -$3.3M | -$7.5M | -$5.8M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud
2026-10-07 · Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
2026-09-23 · Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
2026-07-28 · Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
Price (daily)
Full chart · RSI · MACD · patternsNXTS · daily-37.3% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin